Citations

Clear

3942 citation(s) found for "To, Van".

Making care fit manifesto
Kunneman, Marleen , Griffioen, Ingeborg , Kristiansen, Maria , Beusekom, Mara M. van , Labrie, Nanon , Montori, Víctor M.

Mayo Clinic

BMJ Evidence-Based Medicine | November 23, 2021 | Volume: 28 | Issue: 1 | Pages: 5-6

10.1136/bmjebm-2021-111871 | PMID 34815303 Get It

Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study
Nounu, Aayah , Richmond, Rebecca C. , Stewart, Isobel D., Surendran, Praveen , Wareham, Nicholas J. , Butterworth, Adam S. , Weinstein, Stephanie J. , Figueiredo, Jane C. , Lindor, Noralane M. , Casey, Graham , Marchand, Loı̈c Le , Ulrich, Cornelia M. , Li, Christopher, Dujinhoven, Fränzel van, Gsur, Andrea , Moreno, Vı́ctor , Vodička, Pavel , Vodičková, Ludmila, Alwers, Elizabeth , Chang‐Claude, Jenny , Sakoda, Lori C. , Slattery, Martha L. , Schoen, Robert , Gunter, Marc J. , Castellvı́-Bel, Sergi , Kim, Hyeong Rok , Li, Li , Bishop, D. Timothy , Buchanan, Daniel D. , Gruber, Stephen B. , Rennert, Gad , Harrison, Tabitha A. , Woods, Michael O. , Schafmayer, Clemens , Guelpen, Bethany Van , Gallinger, Steven , Berndt, Sonja I. , Lindblom, Annika , Wu, Anna H. , Peters, Ulrike , Scherer, Dominique , Bermejo, Justo Lorenzo , Brenner, Hermann , Hoffmeister, Michael , Relton, Caroline L. , Drew, David A. , Figueiredo, Jane C , Marchand, Loïc Le , Ulrich, Cornelia M , Gsur, Andrea , Moreno, Victor , Sakoda, Lori C , Castellví-Bel, Sergi , Buchanan, Daniel D , Lorenzo-Bermejo, Justo , Hoffmeister, Michael , Rennert, Gad , Gunter, Marc J , Drew, David A , Harrison, Tabitha A , Van Guelpen, Bethany , Brenner, Hermann , Bishop, D Timothy , Vodicka, Pavel , Lindblom, Annika , Albanes, Demetrius , Baron, John A. , Hopper, John L. , Newcomb, Polly A. , Platz, Elizabeth A. , Campbell, Peter T. , Amitay, Efrat L. , Schoen, Robert, Kweon, Sun-Seog , Chan, Andrew T. , Zheng, Wei , Giles, Graham G. , Stadler, Zsofia , Lin, Yi , Keku, Temitope O , Hampel, Heather , Pharoah, Paul D.P. , Wolk, Alicja , White, Emily , Williams, Ann Caroline

Mayo Clinic

Nutrients | November 21, 2021 | Volume: 13 | Issue: 11 | Pages: 4164

10.3390/nu13114164 | PMID 34836419 Get It

Salicylic acid (SA) has observationally been shown to decrease colorectal cancer (CRC) risk. Aspirin (acetylsalicylic acid, that rapidly deacetylates to SA) is an effective primary and secondary chemopreventive agent. Through a Mendelian randomization (MR) approach, we aimed to address whether levels of SA affected CRC risk, stratifying by aspirin use. A two-sample MR analysis was performed using GWAS summary statistics of SA (INTERVAL and EPIC-Norfolk, N = 14,149) and CRC (CCFR, CORECT, GECCO and UK Biobank, 55,168 cases and 65,160 controls). The DACHS study (4410 cases and 3441 controls) was used for replication and stratification of aspirin-use. SNPs proxying SA were selected via three methods: (1) functional SNPs that influence the activity of aspirin-metabolising enzymes; (2) pathway SNPs present in enzymes’ coding regions; and (3) genome-wide significant SNPs. We found no association between functional SNPs and SA levels. The pathway and genome-wide SNPs showed no association between SA and CRC risk (OR: 1.03, 95% CI: 0.84–1.27 and OR: 1.08, 95% CI: 0.86–1.34, respectively). Results remained unchanged upon aspirin use stratification. We found little evidence to suggest that an SD increase in genetically predicted SA protects against CRC risk in the general population and upon stratification by aspirin use.
Involvement of MAP3K7 in FMD2 and CSCF, delineation of genotype/phenotype correlations.
Senden, Richelle, Konink, Charlotte de , Trezza, Rossella Avagliano , Bassetti, Jennifer A. , Bever, Yolande van , Brooks, Alice S. , Guan, Qiaoning , Klee, Eric W. , Shikany, Amy , Terhal, Paulien A., Wessels, Marja W., Wieringen, Hester van, Gooch, Catherine , Niceta, Marcello , Demirdas, Serwet , Woerden, Geeske M. van , Baban, Anwar , Bird, Lynne M. , Bon, Bregje W.M. van , Marcelis, Carlo , Morales‐Rosado, Joel A. , Schimmenti, Lisa A. , Weaver, Kathryn , Hurst, Anna , Tartaglia, Marco , Elgersma, Ype

Mayo Clinic

No container title available | November 20, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.163741470.06165246/v1 Get It

Mitogen-Activated Protein 3 Kinase 7 (MAP3K7, MIM 602614) encodes the ubiquitously expressed transforming growth factor β (TGF-β)–activated kinase 1 (TAK1), which plays a crucial role in many cellular processes. Variants in the MAP3K7 gene have been linked to 2 distinct disorders: frontometaphyseal dysplasia type 2 (FMD2, MIM #617137) and cardiospondylocarpofacial syndrome (CSCF, MIM #157800). The fact that different variants can induce 2 distinct phenotypes suggests a phenotype/genotype correlation, but no side-by-side comparison has been done thus far to confirm this. Here we significantly expand the cohort and the description of clinical phenotypes for individuals with CSCF and FMD2 who carry variants in MAP3K7. We show that in contrast to FMD2-causing variants, CSCF-causing variants in MAP3K7 have a loss-of-function effect. Additionally, patients with pathogenic variants in MAP3K7 are at risk for cardiac disease, have symptoms associated with connective tissue disease and we show overlap in clinical phenotypes of CSCF with Noonan syndrome. Together, we provide evidence for a molecular fingerprint of FMD2- versus CSCF-causing MAP3K7 variants and conclude that variants in MAP3K7 should be considered in the differential diagnosis of patients with syndromic congenital cardiac defects and/or cardiomyopathy, syndromic connective tissue disorders and in the differential diagnosis of Noonan syndrome.
Plasma IL-2 and Symptoms Response after Acute Gluten Exposure in Subjects With Celiac Disease or Nonceliac Gluten Sensitivity
Cartee, Amanda K. , Choung, Rok Seon , Wang, Suyue , Dyke, Carol T. Van, Hinson, Chadrick A., Marietta, Eric, Katzka, David A. , Nehra, Vandana, Grover, Madhusudan , King, Katherine S. , Van Dyke, Carol T, Dzuris, John L. , Anderson, Robert P. , Murray, Joseph A. , Choung, Rok Seon

Mayo Clinic

American Journal of Gastroenterology | November 19, 2021 | Volume: 117 | Issue: 2 | Pages: 319-326

10.14309/ajg.0000000000001565 | PMID 34797778 Get It

INTRODUCTION: Treated patients with celiac disease (CeD) and nonceliac gluten sensitivity (NCGS) report acute, transient, incompletely understood symptoms after suspected gluten exposure. To determine whether (i) blinded gluten exposure induces symptoms, (ii) subjects accurately identify gluten exposure, and (iii) serum interleukin-2 (IL-2) levels distinguish CeD from NCGS subjects after gluten exposure. METHODS: Sixty subjects (n = 20 treated, healed CeD; n = 20 treated NCGS; n = 20 controls) were block randomized to a single, double-blind sham (rice flour) or 3-g gluten challenge with 72-hours follow-up. Twelve serial questionnaires (100 mm visual analog scale; pain, bloating, nausea, and fatigue) and 10 serial plasma samples were collected. Mucosal permeability was assessed using both urinary lactulose- 13 C mannitol ratios and endoscopic mucosal impedance. RESULTS: Thirty-five of 40 (83%) subjects with CeD and NCGS reported symptoms with gluten (8 CeD, 9 NCGS) and sham (9 CeD, 9 NCGS) compared with 9 of 20 (45%) controls after gluten (n = 6) and sham (n = 3). There was no significant difference in symptoms among groups. Only 2 of 10 subjects with CeD and 4 of 10 NCGS identified gluten, whereas 8 of 10 subjects with CeD and 5 of 10 NCGS identified sham. A significant plasma IL-2 increase occurred only in subjects with CeD after gluten, peaking at 3 hours and normalizing within 24 hours postchallenge despite no significant intestinal permeability change from baseline. DISCUSSION: Symptoms do not reliably indicate gluten exposure in either subjects with CeD or NCGS. IL-2 production indicates a rapid-onset gluten-induced T-cell activation in CeD despite long-standing treatment. The effector site is unknown, given no increased intestinal permeability after gluten.
Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF
Mooney, Leanne , Hawkins, Nathaniel M. , Jhund, Pardeep S. , Redfield, Margaret M. , Vaduganathan, Muthiah , Desai, Akshay S. , Rouleau, Jean L. , Minamisawa, Masatoshi, Shah, Amil M. , Lefkowitz, Martin, Veldhuisen, Dirk J. van , Maggioni, Aldo P. , Claggett, Brian , Solomon, Scott D. , McMurray, John J.V. , Zile, Michael R , Van Veldhuisen, Dirk J , Pfeffer, Marc Alan , Anand, Inder S , Maggioni, Aldo P , Claggett, Brian L , Solomon, Scott David , McMurray, John J V , Jhund, Pardeep S , Desai, Akshay S , Shah, Amil , Zile, Michael R. , Anand, Inder S. , Senni, Michele , Vaduganathan, Muthiah

Mayo Clinic

Journal of the American Heart Association | November 19, 2021 | Volume: 10 | Issue: 23 | Pages: No page available

10.1161/jaha.121.021494 | PMID 34796742 Get It

Background Little is known about the impact of chronic obstructive pulmonary disease (COPD) in patients with heart failure with preserved ejection fraction (HFpEF). Methods and Results We examined outcomes in patients with heart failure with preserved ejection fraction, according to COPD status, in the PARAGON‐HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction) trial. The primary outcome was a composite of first and recurrent hospitalizations for heart failure and cardiovascular death. Of 4791 patients, 670 (14%) had COPD. Patients with COPD were more likely to be men (58% versus 47%; P <0.001) and had worse New York Heart Association functional class (class III/IV 24% versus 19%), worse Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores (69 versus 76; P <0.001) and more frequent history of heart failure hospitalization (54% versus 47%; P <0.001). The decrement in Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores with COPD was greater than for other common comorbidities. Patients with COPD had echocardiographic right ventricular enlargement, higher serum creatinine (100 μmol/L versus 96 μmol/L) and neutrophil‐to‐lymphocyte ratio (2.7 versus 2.5), than those without COPD. After multivariable adjustment, COPD was associated with worse outcomes: adjusted rate ratio for the primary outcome 1.51 (95% CI, 1.25–1.83), total heart failure hospitalization 1.54 (95% CI, 1.24–1.90), cardiovascular death (adjusted hazard ratio [HR], 1.42; 95% CI, 1.10–1.82), and all‐cause death (adjusted HR, 1.52; 95% CI, 1.25–1.84). COPD was associated with worse outcomes than other comorbidities and Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores declined more in patients with COPD than in those without. Conclusions Approximately 1 in 7 patients with heart failure with preserved ejection fraction had concomitant COPD, which was associated with greater functional limitation and a higher risk of heart failure hospitalization and death. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01920711 .
NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT
Winklhofer, Sebastian , Lmalem, Hafida, Brandsma, Dieta , Compter, Annette , Dhermain, F., Glantz, Michael , Hempel, Johann, Jaeckle, Kurt A. , Kumthekar, Priya , O’Brien, Barbara , Postma, Tjeerd J., Schäfer, Niklas , Thust, Steffi, Tonn, Jörg‐Christian, Vogin, Guillaume , Wen, Patrick Y. , Rhun, Émilie Le , Devos, Patrick , Gállego Pérez-Larraya, Jaime , Castellano, Antonella , Franceschi, Enrico , Forsyth, Peter A , Furtner, Julia , Galldiks, Norbert , Gempt, Jens , Hattingen, Elke , Lukacova, Slávka , Minniti, Giuseppe , Roth, Patrick , Rudà, Roberta , Schmidt, Nils Ole , Smits, Marion , Snijders, Tom J , Thust, Steffi, Bent, Martin J. van den , Hoorn, Anouk van der , Preusser, Matthias , Wen, Patrick Yung , Bendszus, Martin , Weller, Michael

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi126-vi127

10.1093/neuonc/noab196.501 Get It

Abstract BACKGROUND Validation of the 2016 LANO MRI scorecard for leptomeningeal metastasis failed for multiple reasons. The objective of this joint EORTC Brain Tumor Group and RANO effort was to validate the feasibility of the revised MRI scorecard for assessing response in leptomeningeal metastasis. METHODS Coded paired cerebrospinal MRI of 20 patients with leptomeningeal metastases from solid cancers at baseline and follow-up after treatment and instructions for assessment were provided via the EORTC imaging platform. The kappa coefficient (K) was used to evaluate inter-observer pairwise agreement. Statistical analyses were performed using SAS V9.4 software (Cary, NC). The sponsor of the study was the University Hospital Zurich (2018-00192). RESULTS Thirty-five raters participated, including 9 neuroradiologists, 17 neurologists, 4 radiation oncologists, 3 neurosurgeons and 2 medical oncologists. Among leptomeningeal metastases-related items at baseline, the best median concordance was noted for hydrocephalus (K=0.63), and the worst median for spinal linear enhancing disease (K=0.46). The median concordance for overall response was moderate (K=0.44). Notably, the interobserver agreement for the presence of parenchymal brain metastases at baseline was minimal (K=0.29). Significant differences were observed when considering the specialty of the raters. Only 394 of 700 ratings (56%) were fully completed. Among 394 fully completed ratings, perfect concordance was noted in 293 ratings (74%) when comparing the overall response according to the guidelines provided in the scorecard and the overall response provided by the raters. The main discordances were noted for partial response according to the rater versus stable disease according to the guidelines (n=44), followed by progression according to the raters versus stable disease according to the guidelines (n=23). CONCLUSION Electronic case report forms with "blocking solutions" are probably required to enforce completeness and quality of scoring. These results confirm the necessity of central review and the need for training of MRI assessment in clinical trials.
Application of myoelectric elbow flexion assist orthosis in adult traumatic brachial plexus injury: a retrospective clinical study
Pulos, Nicholas , Berg, Catherine van den, Shin, Alexander Y., van den Berg, Catherine, Kaufman, Kenton R , Pulos, Nicholas , Berg, Catherine van den, Shin, Alexander Y.

Mayo Clinic

Prosthetics & Orthotics International | November 13, 2021 | Volume: 45 | Issue: 6 | Pages: 521-525

10.1097/pxr.0000000000000046 | PMID 34772869 Get It

Background: Adult traumatic brachial plexus injuries (BPIs) can result in severe impairment following penetrating wounds, falls, and motor vehicle accidents or other high-energy trauma. Objective: Quantify functional outcomes of adult patients with a BPI using a myoelectric orthosis to restore elbow flexion. Study design: Retrospective review. Methods: A clinic specializing in the BPI treatment at a large academic medical center tested nineteen adult patients with BPI. These patients had failed to achieve antigravity elbow flexion following their injury and observation or surgical reconstruction. They were provided a myoelectric elbow orthosis (MEO) if they had detectable electromyography signals. Results: There was significant improvement in strength and significant reductions in function and pain when using an MEO. Following initiation of the MEO, 12 of the 19 patients had clinical improvements in muscle strength, 15 patients showed improvement in their DASH, and 13 patients reported improvements in their Visual Analog Scale. Conclusion: The use of an MEO improves elbow flexion strength, increases function, and reduces pain in the majority of patients with BPI and inadequate elbow flexion following observation or surgical reconstruction.
Respiration‐related variations in Pd/Pa ratio and fractional flow reserve in resting conditions and during intravenous adenosine administration
Feenstra, Rutger G.T. , Lavieren, Martijn A. van, Echavarría‐Pinto, Mauro , Wijntjens, Gilbert , Stegehuis, Valérie, Meuwissen, Martijn , Winter, Robbert J. de , Beijk, Marcel A.M. , Escaned, Javier , Wijntjens, Gilbert W , Piek, Jan J , van de Hoef, Tim P , Escaned, Javier , Lerman, Amir , Hoef, Tim P. van de

Mayo Clinic

Catheterization and Cardiovascular Interventions | November 12, 2021 | Volume: 99 | Issue: 3 | Pages: 844-852

10.1002/ccd.30012 | PMID 34766734 Get It

AbstractAimsWe evaluated the occurrence and physiology of respiration‐related beat‐to‐beat variations in resting Pd/Pa and FFR during intravenous adenosine administration, and its impact on clinical decision‐making.Methods and ResultsCoronary pressure tracings in rest and at plateau hyperemia were analyzed in a total of 39 stenosis from 37 patients, and respiratory rate was calculated with ECG‐derived respiration (EDR) in 26 stenoses from 26 patients. Beat‐to‐beat variations in FFR occurred in a cyclical fashion and were strongly correlated with respiratory rate (R2 = 0.757, p < 0.001). There was no correlation between respiratory rate and variations in resting Pd/Pa. When single‐beat averages were used to calculate FFR, mean ΔFFR was 0.04 ± 0.02. With averaging of FFR over three or five cardiac cycles, mean ΔFFR decreased to 0.02 ± 0.02, and 0.01 ± 0.01, respectively. Using a FFR ≤ 0.80 threshold, stenosis classification changed in 20.5% (8/39), 12.8% (5/39) and 5.1% (2/39) for single‐beat, three‐beat and five‐beat averaged FFR. The impact of respiration was more pronounced in patients with pulmonary disease (ΔFFR 0.05 ± 0.02 vs 0.03 ± 0.02, p = 0.021).ConclusionBeat‐to‐beat variations in FFR during plateau hyperemia related to respiration are common, of clinically relevant magnitude, and frequently lead FFR to cross treatment thresholds. A five‐beat averaged FFR, overcomes clinically relevant impact of FFR variation.